Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate: Difference between revisions
(Created page with "{{DrugProjectFormSinglePage |authorTag={{CMG}};{{AE}};{{DB}} |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> |blackBoxWarningBody=<i><span style="col...") |
No edit summary |
||
| Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | {{DrugProjectFormSinglePage | ||
| | |genericName=Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate | ||
|aOrAn=an | |||
|drugClass=anti- HIV agent | |||
|indicationType=treatment | |||
|indication=HIV infection | |||
|adverseReactions=depressive disorders, insomnia, and headache,diarrhea, nausea, fatigue, dizziness, abnormal dreams, and rash. | |||
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | ||
Revision as of 19:46, 25 August 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate is an anti- HIV agent that is FDA approved for the treatment of HIV infection. Common adverse reactions include depressive disorders, insomnia, and headache,diarrhea, nausea, fatigue, dizziness, abnormal dreams, and rash..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in pediatric patients.
Contraindications
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Contraindications in the drug label.
Warnings
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in geriatric settings.
Gender
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate with respect to specific gender populations.
Race
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Administration in the drug label.
Monitoring
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate and IV administrations.
Overdosage
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Mechanism of Action in the drug label.
Structure
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Structure in the drug label.
Pharmacodynamics
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Clinical Studies in the drug label.
How Supplied
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate How Supplied in the drug label.
Storage
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Disoproxil Fumarate Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.